pH-Sensitive Carbon Nanoparticles for Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods for neurological and cancer treatments face challenges in targeted and efficient release of therapeutics, particularly due to the acidic pH environment of cancer cells, which existing nanocarriers are not optimized to exploit effectively.
Innovation Solution
Development of pH-sensitive graphene oxide nanoparticles (CNPs) that can convert between open and closed forms at specific pH levels, allowing for reversible encapsulation and targeted release of therapeutic agents, including paclitaxel, at acidic pH environments characteristic of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional nanocarriers are used for drug delivery, then drugs can be delivered to disease areas, but they cannot effectively exploit the acidic pH environment of cancer cells for targeted release
Solution Approach 1:
The nanocarrier's structural properties are changed in response to pH parameter variations. The graphene oxide nanoparticle undergoes conformational changes at different pH levels, remaining stable at physiological pH (7.2-7.5) and undergoing structural transformation at acidic pH (6.4-7.0) to release the therapeutic payload, thereby achieving pH-responsive targeted release
Solution Approach 2:
The acidic pH environment, which is normally a harmful characteristic of cancer cells that makes them difficult to target, is converted into a beneficial trigger for drug release. The nanocarrier is designed to remain stable in normal physiological conditions and specifically respond to the acidic environment of tumors, transforming the harmful acidic characteristic into a selective release mechanism
2Reliability
If nanocarriers encapsulate chemotherapeutic agents, then therapeutic efficiency is improved, but the drugs are not released specifically at the target site
Solution Approach 1:
The nanocarrier transitions from a static encapsulated state to a dynamic release state in response to environmental pH changes. The graphene oxide nanoparticle maintains its closed, stable structure during circulation and only opens to release the payload when encountering the acidic tumor microenvironment, achieving controlled and site-specific release
3Reliability
If graphene oxide nanoparticles are designed to convert between open and closed forms at specific pH levels, then pH-specific release is achieved, but the complexity of the nanoparticle structure increases
Solution Approach 1:
Different regions of the graphene oxide nanoparticle have different functional properties. The nanoparticle incorporates carboxylic acid groups and hydroxyl groups at specific locations that confer pH-sensitive behavior, while maintaining a relatively simple overall structure based on reduced graphene oxide, thus achieving pH-specific release without excessive structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pH-sensitive CNPs enable enhanced bioavailability and targeted delivery of therapeutic agents, such as paclitaxel, by releasing the payload specifically at acidic pH, improving treatment efficacy for various cancers, including glioblastoma, with potential for crossing the blood-brain barrier.
Implementation Method 1
graphene oxide nanoparticles (CNP) comprising a plurality of graphene sheets having a plurality of carboxylic acid groups and hydroxyl groups and interconvertible open and closed forms; wherein the closed form can be converted to the open form at a pH of about 6.8 or lower; and the open form can be converted to the closed form at a pH of about 7.0 or greater
Implementation Method 2
the pH-sensitive CNPs enable enhanced bioavailability and targeted delivery of therapeutic agents, such as paclitaxel, by releasing the payload specifically at acidic pH
Data Source
AI summary
Described herein are nanoparticle compositions and methods for pH-specific release and targeted delivery of therapeutics with enhanced bioavailability. In some embodiments, methods are described for generating carbon nanoparticles (CNPs) that can release payload in acidic pH environments.